PROSOMNUS INC (OSA) Fundamental Analysis & Valuation

NASDAQ:OSA • US50535E1082

Current stock price

0.47 USD
-0.05 (-10.29%)
At close:
0.44 USD
-0.03 (-6.38%)
After Hours:

This OSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OSA Profitability Analysis

1.1 Basic Checks

  • OSA had negative earnings in the past year.
  • In the past year OSA has reported a negative cash flow from operations.
OSA Yearly Net Income VS EBIT VS OCF VS FCFOSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

  • OSA has a worse Return On Assets (-49.44%) than 67.18% of its industry peers.
Industry RankSector Rank
ROA -49.44%
ROE N/A
ROIC N/A
ROA(3y)-65.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSA Yearly ROA, ROE, ROICOSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 -100 -200

1.3 Margins

  • The Gross Margin of OSA (52.38%) is comparable to the rest of the industry.
  • The Profit Margin and Operating Margin are not available for OSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSA Yearly Profit, Operating, Gross MarginsOSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. OSA Health Analysis

2.1 Basic Checks

  • OSA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OSA has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, OSA has an improved debt to assets ratio.
OSA Yearly Shares OutstandingOSA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 5M 10M 15M
OSA Yearly Total Debt VS Total AssetsOSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • OSA has an Altman-Z score of -11.52. This is a bad value and indicates that OSA is not financially healthy and even has some risk of bankruptcy.
  • OSA has a worse Altman-Z score (-11.52) than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.52
ROIC/WACCN/A
WACC7.85%
OSA Yearly LT Debt VS Equity VS FCFOSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.53 indicates that OSA should not have too much problems paying its short term obligations.
  • OSA's Current ratio of 1.53 is on the low side compared to the rest of the industry. OSA is outperformed by 83.08% of its industry peers.
  • OSA has a Quick Ratio of 1.38. This is a normal value and indicates that OSA is financially healthy and should not expect problems in meeting its short term obligations.
  • OSA has a worse Quick ratio (1.38) than 71.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.38
OSA Yearly Current Assets VS Current LiabilitesOSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. OSA Growth Analysis

3.1 Past

  • OSA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.77%.
  • Looking at the last year, OSA shows a very strong growth in Revenue. The Revenue has grown by 42.22%.
EPS 1Y (TTM)-28.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
Revenue 1Y (TTM)42.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.4%

3.2 Future

  • OSA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.66% yearly.
  • Based on estimates for the next years, OSA will show a very strong growth in Revenue. The Revenue will grow by 30.56% on average per year.
EPS Next Y-101.05%
EPS Next 2Y-25.09%
EPS Next 3Y4.66%
EPS Next 5YN/A
Revenue Next Year41.66%
Revenue Next 2Y33.46%
Revenue Next 3Y30.56%
Revenue Next 5YN/A

3.3 Evolution

OSA Yearly Revenue VS EstimatesOSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
OSA Yearly EPS VS EstimatesOSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. OSA Valuation Analysis

4.1 Price/Earnings Ratio

  • OSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSA Price Earnings VS Forward Price EarningsOSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSA Per share dataOSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.09%
EPS Next 3Y4.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OSA Dividend Analysis

5.1 Amount

  • No dividends for OSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

OSA Fundamentals: All Metrics, Ratios and Statistics

PROSOMNUS INC

NASDAQ:OSA (4/17/2024, 8:17:27 PM)

After market: 0.44 -0.03 (-6.38%)

0.47

-0.05 (-10.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-26
Earnings (Next)05-10
Inst Owners0.1%
Inst Owner Change0%
Ins Owners23.16%
Ins Owner Change0%
Market Cap8.17M
Revenue(TTM)25.60M
Net Income(TTM)-15.02M
Analysts77.14
Price Target2.55 (442.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.47%
Min EPS beat(2)-103.84%
Max EPS beat(2)96.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.37%
Min Revenue beat(2)-0.46%
Max Revenue beat(2)7.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS1.47
BVpS-1.25
TBVpS-1.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.38%
FCFM N/A
ROA(3y)-65.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 187.18%
Cap/Sales 11.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.38
Altman-Z -11.52
F-Score4
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)54.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
EPS Next Y-101.05%
EPS Next 2Y-25.09%
EPS Next 3Y4.66%
EPS Next 5YN/A
Revenue 1Y (TTM)42.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.4%
Revenue Next Year41.66%
Revenue Next 2Y33.46%
Revenue Next 3Y30.56%
Revenue Next 5YN/A
EBIT growth 1Y-208.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-51.46%
EBIT Next 3Y11.19%
EBIT Next 5YN/A
FCF growth 1Y-135.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.17%
OCF growth 3YN/A
OCF growth 5YN/A

PROSOMNUS INC / OSA Fundamental Analysis FAQ

What is the fundamental rating for OSA stock?

ChartMill assigns a fundamental rating of 1 / 10 to OSA.


Can you provide the valuation status for PROSOMNUS INC?

ChartMill assigns a valuation rating of 0 / 10 to PROSOMNUS INC (OSA). This can be considered as Overvalued.


How profitable is PROSOMNUS INC (OSA) stock?

PROSOMNUS INC (OSA) has a profitability rating of 0 / 10.


How financially healthy is PROSOMNUS INC?

The financial health rating of PROSOMNUS INC (OSA) is 2 / 10.


What is the expected EPS growth for PROSOMNUS INC (OSA) stock?

The Earnings per Share (EPS) of PROSOMNUS INC (OSA) is expected to decline by -101.05% in the next year.